The Prescription Drug User Fee Act's reauthorization last year contributed to a substantial reduction in the backlog of generic drug applications, the FDA said Tuesday. Since passage of the Generic Drug User Fee Amendments, the Office of Generic Drugs has completed work on more than 30% of backlogged applications while easing the hiring of new investigators, project managers, scientific reviewers and support staff, the Center for Drug Evaluation and Research said.

Full Story:
Drug Store News

Related Summaries